Table 3.

Genotypes for genetic polymorphisms in XRCC1, XRCC2, and XRCC3 and their effects on risk of CBP

PolymorphismsCases*
Controls*
OR (95% CI)ORadj (95% CI)χ2P
n (%)n (%)
XRCC1 Arg194Trp3.840.15
    Arg/Arg71 (49.3)51 (37.8)1.001.00
    Arg/Trp56 (38.9)66 (48.9)0.61 (0.37-1.01)0.60 (0.36-1.01)3.680.06
    Trp/Trp17 (11.8)18 (13.3)0.68 (0.32-1.44)0.76 (0.51-1.13)1.850.17
    Arg/Trp+Trp/Trp73 (50.7)84 (62.2)0.62 (0.39-1.01)0.60 (0.37-0.98)§4.180.04
    Trp allele frequency0.310.382.630.11
XRCC1Arg280His7.310.001
    Arg/Arg69 (47.9)87 (64.0)1.001.00
    Arg/His65 (45.1)49 (36.0)1.67 (1.03-2.72)§1.67 (1.02-2.74)§4.180.04
    His/His10 (7.0)0 (0.0)
    Arg/His+His/His75 (52.1)46 (36.0)1.93 (1.20-3.12)1.91 (1.17-3.10)6.740.009
    His allele frequency0.300.186.330.01
XRCC1 Arg399Gln0.960.62
    Arg/Arg60 (41.7)56 (39.7)1.001.00
    Arg/Gln76 (52.8)73 (51.8)0.97 (0.60-1.58)0.99 (0.60-1.60)0.010.93
    Gln/Gln8 (5.6)12 (8.5)0.62 (0.24-1.64)0.80 (0.49-1.33)0.730.39
    Arg/Gln+Gln/Gln84 (58.3)85 (60.3)0.92 (0.58-1.48)0.93 (0.58-1.50)0.080.78
    Gln allele frequency0.320.340.390.53
APE1 Asp148Glu0.610.74
    Asp/Asp52 (35.9)49 (36.0)1.001.00
    Asp/Glu76 (52.4)67 (49.3)1.07 (0.64-1.78)0.98 (0.58-1.64)0.010.93
    Glu/Glu17 (11.7)20 (14.7)0.80 (0.38-1.70)0.79 (0.37-1.70)0.360.55
    Asp/Glu+Glu/Glu93 (64.1)87 (64.0)1.01 (0.62-1.64)0.97 (0.59-1.59)0.010.91
    Asp allele frequency0.380.390.120.73
ADRPT1 Val762Ala0.230.89
    Val/Val74 (51.4)66 (48.5)1.001.00
    Val/Ala59 (41.0)59 (43.4)0.89 (0.55-1.46)0.88 (0.53-1.44)0.290.60
    Ala/Ala11 (7.6)11 (8.1)0.89 (0.36-2.19)0.91 (0.37-2.28)0.040.84
    Val/Ala+Ala/Ala70 (48.6)70 (0.0)0.89 (0.56-1.43)0.86 (0.54-1.39)0.370.54
    Asp allele frequency0.280.300.100.75
XRCC2 Arg188His
    Arg/Arg143 (100.0)137 (100.0)1.001.00
    Arg/His0 (0.0)0 (0.0)
    His/His0 (0.0)0 (0.0)
    Arg/His+His/His0 (0.0)0 (0.0)
His allele frequency0.000.00
XRCC3 Thr241Met0.540.46
    Thr/Thr129 (90.8)119 (88.1)1.001.00
    Thr/Met13 (9.2)16 (11.9)0.75 (0.35-1.62)0.75 (0.34-1.65)0.500.48
    Met/Met0 (0.0)0 (0.0)
    Thr/Met+Met/Met13 (9.2)16 (11.9)0.75 (0.35-1.62)0.75 (0.34-1.65)0.500.48
    Met allele frequency0.050.060.510.48
  • * Some data were missing due to inability to amplify DNA.

  • ORs were adjusted for potential confounding variables including age, sex, exposure duration, and intensity of benzene exposure.

  • Pearson χ2 test for difference in distributions between the case and control groups.

  • § P < 0.05,

  • P < 0.01.